Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer
TL;DR: Altered HLA class I antigen expression occurs in most cervical cancers, is diverse, and is mainly caused by genetic changes, Combined with widespread tumor heterogeneity, these changes have profound implications for natural immunity and T cell–based immunotherapy in cervical cancer.
read more
Abstract: The nature and frequency of human histocompatibility leukocyte antigen (HLA) class I loss mechanisms in primary cancers are largely unknown. We used flow cytometry and molecular analyses to concurrently assess allele-specific HLA phenotypes and genotypes in subpopulations from 30 freshly isolated cervical tumor cell suspensions.
Tumor-associated HLA class I alterations were present in 90% of the lesions tested, comprising four altered pheno/genotype categories: (a) HLA-A or -B allelic loss (17%), mostly associated with gene mutations; (b) HLA haplotype loss, associated with loss of heterozygosity at 6p (50%). This category included cases with additional loss of a (third) HLA-A or -B allele due to mutation, as well as one case with an HLA class I–negative tumor cell subpopulation, caused by a β2-microglobulin gene mutation; (c) Total HLA class I antigen loss and retention of heterozygosity (ROH) at 6p (10%); and (d) B locus or HLA-A/B downregulation associated with ROH and/or allelic imbalance at 6p (10%). Normal HLA phenotypes and ROH at 6p were observed in 10% of the cases. One case could not be classified (3%).
Altered HLA class I antigen expression occurs in most cervical cancers, is diverse, and is mainly caused by genetic changes. Combined with widespread tumor heterogeneity, these changes have profound implications for natural immunity and T cell–based immunotherapy in cervical cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Identification of novel survivin-derived CTL epitopes.
Sine Reker,Anders Meier,Lars Holten-Andersen,Inge Marie Svane,Jürgen C. Becker,Per thor Straten,Mads Hald Andersen +6 more
TL;DR: Describing the characterization of novel HLA-A1-, H LA-A2-, HLA -A3-, and Hla-A11-restricted survivin epitopes on the basis of spontaneous CTL responses in cancer patients significantly increase the number of patients eligible for immunotherapy based on survivin derived peptides.
95
Tumour escape: antitumour effectors too much of a good thing?
TL;DR: Tumour escape from immunosurveillance represents the last series of hurdles to be overcome in formulating truly effective cancer immunotherapy, but given the immense plasticity of the tumour cell, and the complex balance between pro- and antitumour activity of the very same effector pathways, this remains a major challenge.
93
Human Papillomavirus Vaccines.
TL;DR: Human papillomavirus (HPV) vaccines are among the most effective vaccines available, the first to prevent infection by a mucosatropic sexually transmitted infectious agent and to do so without specific induction of mucosal immunity as mentioned in this paper.
90
Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.
TL;DR: Cell lines with downregulated MHC class I expression derived from TC-1 cells may represent a useful model for testing therapeutic anti-HPV vaccines in settings more relevant to clinical requirements.
84
Cytokine profile of cervical cancer cells
TL;DR: The results suggest that cervical carcinoma cells produce immunomodulatory cytokines and that cytokine expression patterns change after malignant transformation, and the implications of locally produced cytokines by cervical cancer cells are suggested.
84
References
The multistep nature of cancer.
TL;DR: Three to six mutations appear to be required to complete the process of cellular multiplication associated with gradual increases in tumor size, disorganization and malignancy in cancer.
2K
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Daniel J. Hicklin,Zhigang Wang,Flavio Arienti,Licia Rivoltini,Giorgio Parmiani,Soldano Ferrone +5 more
TL;DR: Investigation of mechanisms underlying lack of HLA class I antigen expression by melanoma cell lines Me18105, Me9923, and Me1386 suggests that beta2m mutations in melanoma cells may be an early event in progression to the malignant phenotype.
Loss of MHC class‐I expression in cervical carcinomas
Mary E. Connor,Peter L. Stern +1 more
TL;DR: A significant proportion of the cervical carcinomas showed some alteration in MHC class‐I expression, which may allow tumours to evade immune surveillance with more rapid progression and there was, however, no correlation with tumour type, degree of differentiation or stage of disease at presentation.
207
Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression
Patrick Keating,F. V. Cromme,Margaret F Duggan-Keen,P. J. F. Snijders,Jan M. M. Walboomers,Robin D Hunter,Philip A. Dyer,Peter L. Stern +7 more
TL;DR: In this study of 100 carcinomas HLA-A and -B class I expression by the tumour cells was down-regulated at one or more alleles in at least 73% of cervical carcinomas, underlining the importance of single as well as multiple allelic loss in cervical neoplasia.
190
Immune selection after antigen-specific immunotherapy of melanoma.
Adam I. Riker,Janice N. Cormier,Monica C. Panelli,Udai S. Kammula,Ena Wang,Andrea Abati,Patricia Fetsch,Kang Hun Lee,Seth M. Steinberg,Steven A. Rosenberg,Francesco M. Marincola +10 more
TL;DR: This study indirectly demonstrates that vaccination with an MA-derived peptide can result in immune selection in vivo and provides strong immunologic evidence for the specificity of MA vaccines and to the relevance of MA expression in predicting the response to vaccination.
181
Related Papers (5)
[...]